Form 4: Outset Medical General Counsel Awarded Significant Restricted Stock Units

Outset Medical, Inc.'s General Counsel, John L. Brottem, has reported the acquisition of 35,993 Restricted Stock Units (RSUs) as part of his compensation.

Summary

• John L. Brottem, General Counsel of Outset Medical, Inc. (OM), reported the acquisition of 35,993 Restricted Stock Units (RSUs) on June 10, 2025.
• Each RSU represents a contingent right to receive one share of Outset Medical common stock.
• The RSUs are subject to a vesting schedule: 50% will vest on January 17, 2026, and the remaining 50% will vest in equal quarterly installments on February 15, May 15, August 15, and November 15 of the following year (2027).
• Vesting is contingent upon Mr. Brottem's continuous service to the company through the applicable vesting dates.
• Following this transaction, Mr. Brottem's direct beneficial ownership of common stock stands at 47,266 shares.

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units to an executive is generally a positive sign as it aligns management's long-term interests with those of shareholders, indicating commitment and incentivizing performance.

Positives

• The grant of 35,993 Restricted Stock Units (RSUs) to General Counsel John L. Brottem aligns his long-term interests with those of Outset Medical, Inc. shareholders.
• The multi-year vesting schedule, extending through November 2027, incentivizes Mr. Brottem's continued service and commitment to the company's performance and stability.

Risks

• The vesting of the granted RSUs is contingent upon John L. Brottem's continuous service through the specified vesting dates, meaning the RSUs could be forfeited if his employment ceases before full vesting.

Future Outlook

This document does not provide forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on an insider's equity compensation.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation in the form of equity, common across publicly traded companies in all industries, including the medical device sector where Outset Medical operates. It reflects standard practices for aligning executive incentives with shareholder value.

Stakeholder Impact

• Shareholders: The RSU grant aligns the General Counsel's interests with shareholders, potentially leading to more focused long-term decision-making aimed at increasing shareholder value.
• Employees: This compensation structure may serve as a model or incentive for other key employees, reinforcing a performance-based culture.

Next Steps

• The company will continue to monitor and report on the vesting of these RSUs as per the established schedule.
• John L. Brottem's continuous service will be required for the RSUs to vest on the specified dates.

Key Dates

Keywords

Outset Medical, OM, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Executive Compensation, Beneficial Ownership, Corporate Governance